TomaLab
  • CHI SIAMO
    • Mission
    • Codice etico
    • Qualità
    • Amministrazione Trasparente
    • Carta Servizi
  • PAZIENTI
    • Riproduzione e infertilità
    • Oncologia
    • Cardiologia
    • Oftalmologia
  • SPECIALISTI
    • Riproduzione e infertilità
    • Genetica oncologica
    • Anatomia patologica
    • Genetica cardiologica
    • Genetica oftalmologica
    • Genetica forense
    • Malattie rare
  • ISTITUZIONI
  • ESAMI
  • GENET
  • NOTIZIE
    • Articoli
    • Webinar
    • Pubblicazioni
    • LinkedIn
  • CONTATTI
  • SCARICA REFERTI
Seleziona una pagina

Chromosome abnormalities investigated by Non-Invasive Prenatal Testing account for approximately 50% of fetal unbalances associated with relevant clinical phenotypes

Giu 8, 2015

Francesca Romana Grati,1* Andrea Barlocco,1 Beatrice Grimi,1 Silvia Milani,1 Giuditta Frascoli,1 Anna Maria Di Meco,1 Rosaria Liuti,1 Anna Trotta,1 Sara Chinetti,1 Francesca Dulcetti,1 Anna Maria Ruggeri,1 Simona De Toffol,1 Maurizio Clementi,2 Federico Maggi,1 and Giuseppe Simoni1

1Ricerca e Sviluppo, Citogenetica e Biologia Molecolare, TOMA Advanced Biomedical Assays S.p.A., Busto Arsizio, Varese, Italy

2Genetica Clinica, Dipartimento di Pediatria, Universit_a di Padova, Padova, Italy

Am J Med Genet A. 2010 Jun;152A(6):1434-42

During the past 20 years non-invasive screening tests have been increasingly utilized in prenatal diagnosis (PD) practice. Considerable effort has been exerted by multicenter consortia to evaluate the reliability of non-invasive screening tests in detecting those women with an increased risk of having a pregnancy affected by trisomies 21, 18, and 13, monosomy X, and triploidies. To what extent this group of abnormal karyotypes accounts for the total number of phenotypically relevant fetal chromosome abnormalities has, however, never been investigated. The present report is an attempt aimed to quantify this proportion.A retrospective analysis of a homogeneous survey of 115,128 consecutive invasive prenatal tests was undertaken. All cases were classified in accordance with the indication given for the invasive testing. Cytogenetic results regarding 96,416 karyotype analyses performed because of advanced maternal age (_35 years) or gestational anxiety (<35 years) were considered since these are the patients who usually undergo non-invasive screening tests. We calculated the number of cases (T21, T18, T13, 45,X, and triploidy) that would have been detected by prenatal screening onthe basis of the published detectionrate of the combined-2 test or the quadruple test. Our findings indicate that the chromosomal abnormalities investigated by screening tests represent <50%of the fetalchromosomal abnormalities associated with an abnormal outcome ranging from intermediate-to-severe in women <35 years (45.8% and 39.6% in the first and second trimesters, respectively), and sensitivity >50% in women _35 years (65.1% and 61.8%, respectively). To conclude, approximately 50% of the phenotypically relevant abnormal karyotypes cannot be detected by non-invasive prenatal screening tests. _ 2010 Wiley-Liss, Inc.

Clicca qui per l’articolo completo

Meta

  • Accedi
  • Feed dei contenuti
  • Feed dei commenti
  • WordPress.org
Toma Lab logo

TOMA Advanced Biomedical Assays S.p.A.
Società Unipersonale
Via Francesco Ferrer, 25/27 – 21052 Busto Arsizio (VA)
Capitale Soc. 2.050.000€ i.v.
Codice univoco: W7YVJK9
REA CCIAA Varese 155894
C.F. Reg. Impr. e P.IVA 00772010120
Soggetta a direzione e coordinamento di Impact Lab S.p.A.

Contatti
Tel: 0331.652911
Fax: 0331.652919

 
   

Copyright 2020 TomaLab Advanced Biomedical Assays | Powered by Prochemi | Privacy Policy | Cookie Policy | Carta dei servizi